Carmine Fedele

Lab head, Senior Principal Scientist, Oncology/Drug discovery. tweets are my own

[Carmine Fedele @CarminuzzoF]

@raffcolo @HartungIngo Do you have a model to test ADC efficacy in a highly fibrotic TME? PANC CDX models usually lack clinically relevant fibrosis, so it’s unclear whether the ADC can effectively reach tumor cells in this context.

[Lucia Languino @LLanguino]

@LanguinoLu21124 Time to apply for the August 2026 Gordon Research Conference on Extracellular Vesicles: basic science discoveries, biomarker and therapeutic development.
Limited number: GRC allows only 200 participants.
Location: Barcelona, Spain 2026.

[Lucia Languino @LanguinoLu21124]

GRC- Extracellular Vesicles 2026

[Daniel Gerlach @gerlach_d]

Excited to share our recent work on the pan-KRAS inhibitors BI-2493 and BI-2865, displaying potent anti-tumor activity in tumors with #KRAS wild-type allele amplification.

https://t.co/Da3W0Fkydy

Great team effort by team @Boehringer !

[Alice Ting @aliceyting]

Could one envision a synthetic receptor technology that is fully programmable, able to detect diverse extracellular antigens – both soluble and cell-attached – and convert that recognition into a wide range of intracellular responses, from transgene expression and real-time fluorescence to modulation of innate cell behavior (excitation or inhibition of neurons, induction of cell migration, etc.)?

Today we report in Nature a new technology platform that provides a step in that direction: PAGERs, for Programmable Antigen-gated G protein-coupled Engineered Receptors, convert recognition of extracellular soluble or cell-attached antigens into diverse user-selected responses. PAGERs are based on G-protein coupled receptors (GPCRs), which themselves are not structurally modular, but we were able to build in modular antigen gating by fusing an antagonist peptide to the extracellular N-terminal end, and then gating the antagonist with a fused antigen-binding nanobody.  When antigen binds, it sterically interferes with the antagonist, leading to relief of receptor inhibition. Drug or agonist can then turn on PAGER.

https://t.co/Clt8yjyk2y

[Martina Parigi @parigi_martina]

Very excited to share our latest work on the uncoupling of epithelial regeneration and tumorigenesis in the gut! https://t.co/XUGfuPzmSm

[Miriam Molina Arcas @molina_arcas]

Interested on how to combine #KRAS inhibitors with immunotherapies? Check out the last paper of the #Downwardlab and @F_vanMaldegem

[Matt Jones @MattG_Jones]

I'm thrilled to share our new study of the spatial evolution of Kras;p53-driven mouse lung adenocarcinoma! It's been fantastic leading this with @dianyang1117 & @sundakao, and enjoying a long-standing collaboration with @JswLab @YosefLab & @insitubiology. https://t.co/8WfzZPFWTo

[Cancer Cell @Cancer_Cell]

Online Now: The hallmarks of cancer immune evasion https://t.co/2MX95celzx

[Michael Erb @Michael_A_Erb]

Open season on FOXA1! Our paper with the Cravatt group is out today in @MolecularCell. Please check out the updated data, including a new discovery that FOXA1 ligands mirror the effects of a nearby prostate cancer mutation. https://t.co/CiO6oRVx9N (1/2)

[Rodrigo Romero Rangel @RRomero_PhD]

🚨🚨Now online @NatureCancer, my postdoc work in @SawyersLabMSKCC with @dana_peer 🚨🚨 we establish a powerful organoid transplantation model of prostate cancer neuroendocrine transformation. Open access for all! @HHMINEWS
https://t.co/FJc0WSBvDQ
A 🧵... /1

[Rei Kudo_MDPhD @Reik0110]

Delighted to share our research @Cancer_Cell @MSKCancerCenter ! We explore the mechanisms behind variable #BreastCancer responses to CDK4/6 inhibitors. TP53 mutation is linked to lack of long-term disease control.
https://t.co/VK4gRpkp70

[Ferdinandos Skoulidis @FSkoulidis]

Excited to share our new study @Nature. Very grateful for the support of our collaborators, pharma and biotech partners and members of the Skoulidis and Heymach labs. Special thanks to star fellow @_hanielaraujo and @minhtruongdo. Thankful to our patients. @MDAndersonNews

[Panayiotis Anastasiou @Anastap78]

Excited to share the data from my PhD project!! 🎉 Thank you to all the people that were involved!! 🙏

[Miriam Molina Arcas @molina_arcas]

Excited to share our last paper out today in @NatureComms Led by the talented @Anastap78 #KRAS #immunotherapies #NSCLC

[Alessio Ciulli @alessiociulli]

Thrilled to share that, together with my colleagues @UoDCeTPD and collaborators @Boehringer, we report @ScienceMagazine the breakthrough discovery and characterization of a small-molecule that degrades most oncogenic mutant forms of KRAS. 1/8 https://t.co/PT8miaXUnR

[Anirban Maitra @Aiims1742]

The @Boehringer KRAS degrader in @ScienceMagazine
https://t.co/P2fqGRZpsn
Perspective from Adrienne Cox & @cjder23
https://t.co/04U0o3vl9W

[Johannes Morstein @mo_hannes]

Excited to share our study in @CellCellPress on expanding the druggability of GTPases beyond K-Ras and start putting the entire family (150+ proteins) on the map of drug discovery! @kevansf @UCSF @UCSFCancer @HHMINEWS (1/7)

https://t.co/1AO6hxYKUy

[Cancer Cell @Cancer_Cell]

Online Now: Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer https://t.co/hveC9X9Pmd

[Ryan Potts @pottslab]

New print posted from the group @Amgen. We describe VIPER-TACs that leverage viral E3 ligases for disease-specific targeted protein degradation. This concept dramatically expands he druggable space to include pan-essential proteins. 🧵 #mycompany https://t.co/UwgRpIbeAL